Skip to main content
. Author manuscript; available in PMC: 2022 Dec 24.
Published in final edited form as: J Health Polit Policy Law. 2022 Dec 1;47(6):691–708. doi: 10.1215/03616878-10041121

Table 1.

Direct Acting Antivirals Approved for the Treatment of Hepatitis C in the U.S.

FDA Approval Date Pharmaceutical Company Brand or Generic Brand Name Active Ingredients
December, 2013 Gilead Sciences, Inc. Brand Sovaldi Sofosbuvir
October, 2014 Gilead Sciences, Inc. Brand Harvoni Ledipasvir/sofosbuvir
June, 2016 Gilead Sciences, Inc. Brand Epclusa Sofosbuvir/velpatasvir
July. 2017 Gilead Sciences, Inc. Brand Vosevi Sofosbuvir/velpatasvir/voxilaprevir
January, 2019 Asegua Therapeutics Authorized generic N/A Sofosbuvir/velpatasvir
January, 2019 Asegua Therapeutics Authorized generic N/A Ledipasvir/sofosbuvir
December, 2014 AbbVie Inc. Brand Viekira Pak Ombitasvir/paritaprevir/ritonavir/dasabuvir
July. 2015 AbbVie Inc. Brand Technivie Ombitasvir/paritaprevir/ritonavir
July, 2016 AbbVie Inc. Brand Viekira XR Dasabuvir/ombitasvir/paritaprevir/ritonavir
August, 2017 AbbVie Inc. Brand Mavyret Glecaprevir/pibrentasvir
January, 2016 Merck Brand Zepatier Elbasvir/grazoprevir